Results 161 to 170 of about 34,994 (236)

Integrative multi-omics and single-cell analysis identifies EGFR pathway activation and metabolic reprogramming as potential synthetic lethal vulnerabilities in resistance to the FGFR inhibitor AZD4547. [PDF]

J Transl Med
Tan L, Hou T, Ying P, Wang X, Jin H, Luo J.   +5 more
europepmc   +1 more source

Modern therapeutic approaches in cholangiocarcinoma: A narrative review of key biomarkers and clinical trials. [PDF]

Transl Oncol
Almeida A, Manzi J, Hoff C, Kadri H, Livingstone A, Gleisner A, Toegel EB, Schulick R, Hoff PM, Vianna R, Abreu P.   +10 more
europepmc   +1 more source

<i>FGFR3</i> gene alteration and protein expression in upper urinary tract carcinoma: unsuitability of ureteroscopic biopsy specimens for <i>FGFR3</i> RNA testing. [PDF]

Explor Target Antitumor Ther
Miyake M, Oda Y, Nishimura N, Ohnishi S, Miyazaki K, Shimizu T, Owari T, Iida K, Fujimoto K.   +8 more
europepmc   +1 more source

Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer. [PDF]

Cancer Res Commun
Richardson AB, Chatterjee P, Rosati R, Rajewski A, Diaz RL, Appleyard LR, Pereira S, Bernard B, Javle MM, King GG, Diehl A, Harris WP, Roychowdhury S, Kemp CJ, Grandori C.   +14 more
europepmc   +1 more source

FGFR gets biased [PDF]

Nature Chemical Biology, 2013
openaire   +1 more source

FGFR inhibitor resistance in cervical cancer: a role for integrin α2 and mTOR signalling. [PDF]

Front Cell Dev Biol
Bou Antoun N, Grose RP, Walker AJ, Modjtahedi H, Chioni AM.   +4 more
europepmc   +1 more source

FGFR Inhibitor ASP5878 [PDF]

, 2020
openaire   +1 more source

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial. [PDF]

Nat Commun
Zhang P, Niu Z, Guo H, Zhang M, Jiang S, Cao B, He C, Hou X, Zhang J, Yuan J, Zhu Y, Yu Y, Sun C, Peng P, Fan J, Gong J, Zhou J, Shen L.   +17 more
europepmc   +1 more source

Transcriptomic Stratification Reveals an FRS2-Associated, Proliferation-Independent Phenotype in MDM2-High Sarcomas. [PDF]

Curr Oncol
Sakai T, Aiba H, Yamaguchi M, Hagiwara K, Murakami H, Kimura H.   +5 more
europepmc   +1 more source

Decoding FGFR inhibitor sensitivity in cholangiocarcinoma with interpretable machine learning and cross-platform pharmacogenomic validation. [PDF]

Front Pharmacol
Xie Y, Li H, Zhang W, Sun S, Zhang J, Wang L.   +5 more
europepmc   +1 more source